Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity

References

• Titlic M, Kodzoman K, Loncar D. Neurologic manifestations of hypereosinophilic syndrome–review of the literature. Acta Clin Croat. 2012;51:65–69.
   PubMed Web of Science ®Google Scholar
• Inayat F, Hurairah A. Gastrointestinal and Hepatic Involvement in Hypereosinophilic Syndrome. Cureus. 2016;8:e760. doi:10.7759/cureus.760.
   PubMed Web of Science ®Google Scholar
• Ortiz C, Jimenez M, Matos NA. Chronic eosinophilic leukemia: a rare cause of hypereosinophilic syndrome. Bol Asoc Med P R. 2014;106:33–36.
   PubMedGoogle Scholar
• Park SM, Park JW, Kim SM, Koo EH, Lee JY, Lee CS, Choi DC, Lee BJ. A case of hypereosinophilic syndrome presenting with multiorgan infarctions associated with disseminated intravascular coagulation. Allergy Asthma Immunol Res. 2012;4:161–164. doi:10.4168/aair.2012.4.3.161.
   PubMed Web of Science ®Google Scholar
• Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015;126:1069–1077. doi:10.1182/blood-2014-11-551614.
   PubMed Web of Science ®Google Scholar
• Fraticelli P, Kafyeke A, Mattioli M, Martino GP, Murri M, Gabrielli A. Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. World J Clin Cases. 2016;4:328–332. doi:10.12998/wjcc.v4.i10.328.
   PubMed Web of Science ®Google Scholar
• Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007;2:37. doi:10.1186/1750-1172-2-37.
   PubMed Web of Science ®Google Scholar
• Savage N, George TI, Gotlib J. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. Int J Lab Hematol. 2013;35:491–500. doi:10.1111/ijlh.12057.
   PubMed Web of Science ®Google Scholar
• Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103:2879–2891. doi:10.1182/blood-2003-06-1824.
   PubMed Web of Science ®Google Scholar
• Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214. doi:10.1056/NEJMoa025217.
   PubMed Web of Science ®Google Scholar
• Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21:1183–1188. doi:10.1038/sj.leu.2404662.
   PubMed Web of Science ®Google Scholar
• Waller CF. Imatinib mesylate. Recent Results Cancer Res. 2014;201:1–25. doi:10.1007/978-3-642-54490-3_1.
   PubMedGoogle Scholar
• Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, Nupponen NN, Joensuu H. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol. 2005;23:49–57. doi:10.1200/jco.2005.02.093.
   PubMed Web of Science ®Google Scholar
• Qian C, Wong CWY, Wu Z, He Q, Xia H, Tam PKH, Wong KKY, Lui VCH. Stage specific requirement of platelet-derived growth factor receptor-alpha in embryonic development. PLoS One. 2017;12:e0184473. doi:10.1371/journal.pone.0184473.
   Google Scholar
• Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, Serve H, Cross NC, Hochhaus A, Hofmann WK, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood. 2011;117:2935–2943. doi:10.1182/blood-2010-05-286757.
   PubMed Web of Science ®Google Scholar
• Hiwatari M, Taki T, Tsuchida M, Hanada R, Hongo T, Sako M, Hayashi Y. Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor alpha(PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22). Leukemia. 2005;19:476–477. doi:10.1038/sj.leu.2403638.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Nakagawa S, Fukunaga T, Fukuoka S, Hatakeyama K, Hayashi T. Acute necrotizing eosinophilic myocarditis successfully treated by high dose methylprednisolone. Jpn Circ J. 2001;65:923–926.
   PubMedGoogle Scholar
• Shah S, Loghavi S, Garcia-Manero G, Khoury JD. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. J Hematol Oncol. 2014;7:26. doi:10.1186/1756-8722-7-26.
   PubMed Web of Science ®Google Scholar
• Kumar AN, Sathyanarayanan V, Devi VL, Rajkumar NN, Das U, Dutt S, Chinnagiriyappa LK. FIP1L1-PDGFRA-positive chronic eosinophilic leukemia: a low-burden disease with dramatic response to imatinib - a report of 5 cases from South India. Turk J Haematol. 2014;31:56–60. doi:10.4274/Tjh.2013.0086.
   PubMed Web of Science ®Google Scholar
• Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207. doi:10.1186/s12943-015-0474-2.
   PubMed Web of Science ®Google Scholar
• Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 2015;47:1061–1066. doi:10.1038/ng.3358.
   PubMed Web of Science ®Google Scholar
• Duployez N, Micol JB, Boissel N, Petit A, Geffroy S, Bucci M, Lapillonne H, Renneville A, Leverger G, Ifrah N, et al. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). Leuk Lymphoma. 2016;57:199–200. doi:10.3109/10428194.2015.1037754.
   PubMed Web of Science ®Google Scholar